April 20, 2024
Market Now
LegoChem Bio’s TB medicine wins USFDA’s QIDP approval
[DISCLOSURE] LegoChem Bio (141080) announced on Sept. 18 that its LCB01-0371, a tuberculosis therapy, has been granted as qualified infectious disease product by USFDA.
This will secure exclusive market monopoly for five years, priority review for novel drugs and fast track rights for approval from USFDA, said the company.
By Hwang You-mee (glamazon@heraldcorp.com)
This will secure exclusive market monopoly for five years, priority review for novel drugs and fast track rights for approval from USFDA, said the company.
By Hwang You-mee (glamazon@heraldcorp.com)
